


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:13Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405434" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405434</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>cddis</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Death Dis</journal-id><journal-id journal-id-type="iso-abbrev">Cell Death Dis</journal-id><journal-id journal-id-type="pmc-domain-id">1437</journal-id><journal-id journal-id-type="pmc-domain">cddis</journal-id><journal-title-group><journal-title>Cell Death &amp; Disease</journal-title></journal-title-group><issn pub-type="epub">2041-4889</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405434</article-id><article-id pub-id-type="pmcid-ver">PMC12405434.1</article-id><article-id pub-id-type="pmcaid">12405434</article-id><article-id pub-id-type="pmcaiid">12405434</article-id><article-id pub-id-type="pmid">40897694</article-id><article-id pub-id-type="doi">10.1038/s41419-025-07981-7</article-id><article-id pub-id-type="publisher-id">7981</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Targeted deprivation of STAT6 sensitizes acute lymphoblastic leukemia cells to cytarabine in vivo and in vitro: clinical implications</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Sun</surname><given-names initials="S">Shuzhang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Cheng</surname><given-names initials="Y">Yixuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Huang</surname><given-names initials="X">Xiange</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yan</surname><given-names initials="Y">Yinjie</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hou</surname><given-names initials="W">Wanxin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="H">Houshun</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yao</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="C">Chunshuang</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="Y">Yiming</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="Z">Zhiyi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6692-8221</contrib-id><name name-style="western"><surname>Assaraf</surname><given-names initials="YG">Yehuda G.</given-names></name><address><email>assaraf@technion.ac.il</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2860-694X</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="H">Hui</given-names></name><address><email>lihui@scmc.com.cn</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="H">Hegen</given-names></name><address><email>Shlaogen@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4254-8117</contrib-id><name name-style="western"><surname>Xiao</surname><given-names initials="N">Ning</given-names></name><address><email>xiaoning86@sjtu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00z27jk27</institution-id><institution-id institution-id-type="GRID">grid.412540.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2372 7462</institution-id><institution>Institute of Traditional Chinese Medicine Surgery, Longhua Hospital, </institution><institution>Shanghai University of Traditional Chinese Medicine, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00z27jk27</institution-id><institution-id institution-id-type="GRID">grid.412540.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2372 7462</institution-id><institution>Department of Oncology, Longhua Hospital, </institution><institution>Shanghai University of Traditional Chinese Medicine, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00z27jk27</institution-id><institution-id institution-id-type="GRID">grid.412540.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2372 7462</institution-id><institution>Department of Medical Affairs, Longhua Hospital, </institution><institution>Shanghai University of Traditional Chinese Medicine, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0220qvk04</institution-id><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution>Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children&#8217;s Medical Center, School of Medicine, </institution><institution>Shanghai Jiao Tong University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00hagsh42</institution-id><institution-id institution-id-type="GRID">grid.464460.4</institution-id><institution>Department of Oncology, </institution><institution>Tianshan Hospital of Traditional Chinese Medicine in Changning District, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qryx823</institution-id><institution-id institution-id-type="GRID">grid.6451.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2110 2151</institution-id><institution>The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, </institution><institution>Technion-Israel Institute of Technology, </institution></institution-wrap>Haifa, Israel </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0220qvk04</institution-id><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution>Fujian Children&#8217;s Hospital, </institution><institution>Fujian Branch of Shanghai Children&#8217;s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, </institution></institution-wrap>Fujian, China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">478458</issue-id><elocation-id>669</elocation-id><history><date date-type="received"><day>21</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>28</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41419_2025_Article_7981.pdf"/><abstract id="Abs1"><p id="Par1">Chemotherapy is the leading treatment for acute lymphoblastic leukemia (ALL). However, many ALL patients eventually develop relapses, the treatment of which remains a major challenge due to their chemoresistance phenotype. As a step towards this end, we here uncovered that relapsed ALL specimens exhibit a significantly lower expression of <italic toggle="yes">STAT6</italic> but not of other <italic toggle="yes">STATs</italic>, when compared with their paired diagnosis specimens. Furthermore, STAT6 plays a distinctive role in chemosensitization of ALL cells to cytarabine (Ara-C), and T-box transcription factor 21 <italic toggle="yes">(TBX21)</italic> emerged as a plausible intrinsic biomarker of this Ara-C chemosensitization. We demonstrate that STAT6 undergoes SUMOylation on Lys-307 and sentrin/SUMO-specific protease 3 (SENP3)-mediated deSUMOylation in ALL cells. Most importantly, Ara-C specifically induced SENP3 expression and SENP3 knockdown sensitized ALL cells to Ara-C, with an impact equivalent to STAT6 knockout. These findings support the feedback resistance conferred upon ALL cells by Ara-C-induced SENP3 expression. Our findings uncover a novel role for STAT6 in ALL resistance to Ara-C and suggest that its targeted deprivation or pharmacological inhibition specifically sensitizes ALL cells to Ara-C, offering a plausible modality to surmount Ara-C resistance in future ALL treatment.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Translational research</kwd><kwd>Prognostic markers</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>81872252</award-id><award-id>82070159</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Hui</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Ning</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100010876</institution-id><institution>Shanghai University of Traditional Chinese Medicine (Shanghai University of TCM)</institution></institution-wrap></funding-source><award-id>KY22012</award-id><principal-award-recipient><name name-style="western"><surname>Yan</surname><given-names>Yinjie</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003399</institution-id><institution>Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission)</institution></institution-wrap></funding-source><award-id>21MC1930500</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Hegen</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100007279</institution-id><institution>Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau)</institution></institution-wrap></funding-source><award-id>shslczdzk03701</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Hegen</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Associazione Differenziamento e Morte Cellulare ADMC 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Acute lymphoblastic leukemia (ALL) is an aggressive malignancy of lymphoid progenitor cells, and it can invade the bone marrow, blood, and extramedullary sites, with a peak incidence occurring in early childhood and older age [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The first-line treatment for ALL typically comprises four phases over 2&#8211;3 years, including induction, consolidation, intensification, and long-term maintenance. In this regard, multimodal chemotherapy forms the therapeutic base of ALL therapy [<xref ref-type="bibr" rid="CR3">3</xref>]. To date, disease-risk stratification and the development of intensified chemotherapy protocols has substantially improved the outcome of ALL patients, particularly children whose 5-year overall survival rate exceeds 90% [<xref ref-type="bibr" rid="CR4">4</xref>]. However, 15%&#8211;20% of ALL patients eventually experience relapses. In addition, the treatment of relapsed ALL remains a true challenge since not only the survival rate lags well behind that observed at initial diagnosis, but the outcome also aggravates at the second or later relapse [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, deciphering the molecular mechanisms underlying chemoresistance and the development of novel modalities to surmount chemoresistance is of paramount importance in the future treatment of ALL.</p><p id="Par3">The protein family of signal transducer and activator of transcription (STAT) comprises seven structurally and functionally related members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 [<xref ref-type="bibr" rid="CR6">6</xref>]. Upon stimulation by specific extracellular signals, for instance, cytokines and growth factors, STATs promote the rapid transcription of target genes through a canonical paradigm. Specifically, the latent cytoplasmic STATs become rapidly tyrosine-phosphorylated by Janus kinases after receptor activation, which then facilitates their dimerization and subsequent nuclear translocation to activate gene expression [<xref ref-type="bibr" rid="CR7">7</xref>]. A growing number of studies have also uncovered noncanonical STAT functions that lie outside this canonical paradigm, such as gene repression, non-nuclear roles, and functions independent of tyrosine phosphorylation [<xref ref-type="bibr" rid="CR8">8</xref>]. Individual STAT gene ablations corroborated their essential physiological roles, particularly in blood and immune cell, and various functions in mammopoiesis, lactation, postnatal growth, and homeostatic processes [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. In contrast, the potential role of STATs in relapsed ALL remains poorly understood. In the current study, relapsed ALL specimens exhibited a significantly lower expression of <italic toggle="yes">STAT6</italic> but not of other <italic toggle="yes">STATs</italic>, when compared with the paired diagnosis specimens. Moreover, knockout or pharmacological inhibition of STAT6 specifically sensitized ALL cells to the central anti-leukemia drug cytarabine (Ara-C) and increased the incidence of Ara-C-induced apoptosis without altering the normal growth of ALL cells. RNA-Seq results indicate that T-box transcription factor 21 (<italic toggle="yes">TBX21</italic>) can serve as an intrinsic indicator implicated in this Ara-C sensitization of ALL cells. Hence, targeting STAT6 readily sensitizes ALL cells to Ara-C. In this respect, we further found that the anticancer drug monomer Tanshinone &#8544; (TS1), a natural o-quinone [<xref ref-type="bibr" rid="CR12">12</xref>], synergized with Ara-C to induce apoptosis in ALL cells by reducing STAT6 levels; this synergistic effect was directly proportional to the immediate status of <italic toggle="yes">TBX21</italic> transcription. Furthermore, we show for the first time that STAT6 underwent SUMOylation on Lys-307 and sentrin/SUMO-specific protease 3 (SENP3)-mediated deSUMOylation in ALL cells. Importantly, Ara-C specifically induced SENP3 expression in ALL cells, and SENP3 knockdown markedly sensitized ALL cells to Ara-C with an impact equivalent to STAT6 targeting. This finding supports the feedback resistance conferred upon ALL cells by Ara-C-induced SENP3. Collectively, our findings reveal a novel role of STAT6 in ALL cell sensitivity to Ara-C and demonstrate the effectiveness of multiple strategies against STAT6, offering a plausible modality to treat ALL via STAT6 targeting.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec3"><title>Cell culture and transfection</title><p id="Par4">The human ALL cell lines REH, 697, and NALM6 were cultured in RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Human embryonic kidney 293T (HEK293T) cells were cultured in DMEM (Gibco). All media were supplemented with 10% fetal bovine serum (Gibco), 100&#8201;U/mL penicillin (Thermo Fisher Scientific), and 0.1&#8201;mg/mL streptomycin (Thermo Fisher Scientific). Cells were incubated at 37 &#176;C under 5% CO<sub>2</sub>. Cell lines were regularly authenticated and tested for mycoplasma contamination. Transfections were conducted by FuGENE 6 (Promega, Madison, WI, USA) and jetPRIME (Polyplus-transfection, Illkirch, France) according to the manufacturer&#8217;s instructions.</p></sec><sec id="Sec4"><title>Generation of knockout/knockdown/stable cell lines</title><p id="Par5">Construction of a knockout cell line has been described previously [<xref ref-type="bibr" rid="CR13">13</xref>]. Briefly, the CRISPR/Cas9 system was used to knockout genes. sgRNA was designed based on the information available at <ext-link ext-link-type="uri" xlink:href="http://crispr.mit.edu">http://crispr.mit.edu</ext-link> and cloned into a vector by following the Zhang laboratory&#8217;s protocol. The sgRNA sequences were as follows: STAT6-1#, 5&#8217;-CCCTCACCAGGTTCTTGAAC-3&#8217;; STAT6-2#, 5&#8217;- CATCAACAACACTGTGCCCT-3&#8217;; TBX21-1#, 5&#8217;-CACCGGTTGTGGCCAAGTTTAATC-3&#8217;; TBX21-2#, 5&#8217;-CACCGCTACAGGATGTTTGTGGACG-3&#8217;. Construction of knockdown or stably-expressed cell lines was described in our previous study [<xref ref-type="bibr" rid="CR14">14</xref>]. Cells were infected with lentivirus and selected with l &#956;g/mL puromycin (Thermo Fisher Scientific).</p></sec><sec id="Sec5"><title>Cell viability assay</title><p id="Par6">The cell viability assay has been described previously [<xref ref-type="bibr" rid="CR15">15</xref>]. Briefly, cells were seeded in 96-well plates (1.5&#215;10<sup>4</sup> cells/well) and treated with increasing drug concentrations for 72&#8201;h. Cell viability was determined by CellTiter-Glo Luminescent Kit (Promega) according to the manufacturer&#8217;s instructions. The half maximal inhibitory concentration (IC<sub>50</sub>) was calculated with GraphPad Prism software. For the growth curve, cells were seeded in 96-well plates (1 &#215; 10<sup>4</sup> cells/well), and cell viability was detected by CellTiter-Glo Luminescent Kit (Promega) once a day for 5 days. The relative growth rate at different time points was calculated with day 0 as the control.</p></sec><sec id="Sec6"><title>Mouse xenograft model</title><p id="Par7">Xenograft models of human ALL were established in B-NDG (NOD-<italic toggle="yes">Prkdc</italic><sup><italic toggle="yes">scid</italic></sup>
<italic toggle="yes">IL2rg</italic><sup><italic toggle="yes">tm1</italic></sup>/Bcgen) mice (Biocytogen, Beijing, China). Parental REH, STAT6 knockout or SENP3 knockout REH cells (1.5 &#215; 10<sup>7</sup> cells/mouse) were injected into the tail vein of female NDG mice aged 6-8 weeks. After approximately 2 weeks, mice were intraperitoneally treated with Ara-C (500&#8201;mg/kg for 2 days), and then mice were sacrificed, bone marrow cells were isolated from the tibia bone, and CD19-positive cells were analyzed by flow cytometry. Animal studies were approved by the Institutional Animal Care and Use Committee of Shanghai Children&#8217;s Medical Center.</p></sec><sec id="Sec7"><title>Real-time PCR</title><p id="Par8">Total cellular RNA was extracted using Trizol reagent (TIANGEN, Beijing, China). One &#956;g of total RNA was used for reverse transcription into cDNA by the PrimeScriptTM RT reagent kit with cDNA Eraser (Takara, Japan). Q-PCR reactions were performed with SYBR green reagent (Takara, Japan) by a real-time PCR thermocycler (Agilent, USA). Primers used for Q-PCR were as follows: <italic toggle="yes">STAT6</italic>, forward-CCACTTTCAGACAAATACTTCA, reverse-GAGTTCTTCCTGCTTCCA; <italic toggle="yes">TBX21</italic>, forward-TTCCAACACGCATATCTT, reverse-AGTAATCTCGGCATTCTG; <italic toggle="yes">FRK</italic>, forward-AATGCCTTACAGTGGTATGA, reverse-GATGGTTGCGGAAGTCTA; <italic toggle="yes">GPRIN3</italic>, forward-CCTACTGCTCAATCCTAA, reverse-CTCCTGGTTCTTCCTAAT; <italic toggle="yes">GAPDH</italic>, forward-GAGCTGAACGGGAAGCTCACTG, reverse-TGGTGCTCAGTGTAGCCCAGGA.</p></sec><sec id="Sec8"><title>Cell apoptosis assay</title><p id="Par9">Cells were seeded in 12-well plates (1 &#215; 10<sup>5</sup> cells/well) and incubated with the indicated drugs for 72&#8201;h. Cells were then harvested for staining by Annexin V apoptosis detection kit (Elabscience, China), and the percentage of Annexin V-positive cells was determined using a FACSCalibur flow cytometer (BD Biosciences, USA).</p></sec><sec id="Sec9"><title>Immunoprecipitation and Western blot analysis</title><p id="Par10">The immunoprecipitation and Western blotting protocols have been described previously [<xref ref-type="bibr" rid="CR16">16</xref>]. Immunoprecipitates and cell lysates were analyzed by SDS-PAGE and proteins of interest were detected using the following antibodies: STAT6 (ab32520, Abcam, Cambridge, United Kingdom), p-Y641-STAT6 (ab263947), &#947;H2AX (ab81299); H2AX (#7631S, Cell Signaling Technology, Dallas, TX, USA), Cleaved PARP (#5625S), PARP (#9542S), SUMO1 (#4930), SUMO2/3 (#4971), GST-Tag (#2624); Actin (R1207-1, HUABIO) and GAPDH (R1207-1); SENP2 (GTX110504, GeneTex); SENP3 (A303-139A, Bethyl Laboratories, Montgomery, TX, USA); FLAG M2 Affinity Gel (A2220, MilliporeSigma, Burlington, MA, USA) and anti-FLAG M2 (F3165); HA-Tag (66006-1-Ig, Proteintech) and Myc-Tag (60003-2-Ig). Immunoblots were imaged and analyzed using the Odyssey system (LI-COR Biosciences, USA), ImageQuant LAS4000 (GE Healthcare, USA), or ChemiDoc MP (BioRad, USA).</p></sec><sec id="Sec10"><title>Prokaryotic SUMO-conjugation system</title><p id="Par11">The prokaryotic SUMOylation system was previously described [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Briefly, GST-tagged recombinant plasmids pGEX-STAT6-WT/K307R/K621R were separately co-transfected with pE1E2S1 (or pE1E2S2) into <italic toggle="yes">Escherichia coli</italic> BL21 (DE3) competent cells and then grown on the plate coated with chloramphenicol and ampicillin LB. The colonies were transferred to liquid LB medium, and 0.2&#8201;mM isopropyl-&#946;-D-thiogalactopyranoside was added when OD<sub>600</sub> reached 0.6. Next, the bacterial suspension was incubated for 12&#8201;h at 25 &#176;C and then harvested for the purification of SUMOylated proteins by GST-pull down assay.</p></sec><sec id="Sec11"><title>RNA sequencing</title><p id="Par12">Cells were seeded in 12-well plates (1 &#215; 10<sup>5</sup> cells/well), and lysed with Trizol reagent. Establishment of cDNA library, RNA sequence analysis, quality control,l and transcriptome profiling were performed by TIANGEN Biotech Co., Ltd (Beijing, China). Details can be found on the official website: <ext-link ext-link-type="uri" xlink:href="https://www.tiangen.com">https://www.tiangen.com</ext-link>.</p></sec><sec id="Sec12"><title>Quantification and statistical analysis</title><p id="Par13">Sample sizes and reproducibility for each figure are denoted in the figure legends. Statistical analysis and associated statistical graphics were established by GraphPad Prism software. Statistical significance between conditions was calculated using two-tailed Student&#8217;s t-tests, NS: <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Error bars denote the S.D. All statistical details can be found in the methods and/or figure legends.</p></sec></sec><sec id="Sec13" sec-type="results"><title>Results</title><sec id="Sec14"><title>STAT6 deprivation sensitizes ALL cells to Ara-C</title><p id="Par14">To assess the potential roles of STATs in relapsed ALL, we re-analyzed RNA-Seq data from 53 matched pairs of diagnosis-relapse ALL specimens [<xref ref-type="bibr" rid="CR18">18</xref>]. The results reveal a significantly lower expression of <italic toggle="yes">STAT6</italic> but not of other <italic toggle="yes">STATs</italic> in relapsed specimens than in diagnosis specimens (Fig. <xref rid="Fig1" ref-type="fig">1A</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">1A</xref>). This finding raised the question of whether STAT6 plays specific roles in ALL relapse. Towards this end, we firstly deprived the human ALL cell line REH of its endogenous STAT6 using CRISPR-Cas9 knockout to assess the possible impact of STAT6 on the chemosensitivity of ALL cells (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). Notably, upon treatment with Ara-C, the viability of STAT6-knockout REH cells markedly decreased when compared with the control cells (Fig. <xref rid="Fig1" ref-type="fig">1D</xref>). Remarkably, these cells presented minimal differences from the control cells after treatment with other common chemotherapeutic drugs used for ALL therapy, including methotrexate (MTX), 6-mercaptopurine (6-MP), vincristine (VCR), L-asparaginase (L-Asp), and daunorubicin (DNR) (Supplementary Fig. <xref rid="MOESM3" ref-type="media">1B&#8211;F</xref>). Consistently, similar results were obtained with the other two ALL cell lines, NALM6 and 697, hence corroborating the enhanced chemosensitivity of ALL cells to Ara-C via STAT6 knockout (Supplementary Fig. <xref rid="MOESM3" ref-type="media">1G&#8211;I</xref>). Furthermore, pharmacological inhibition of STAT6 by AS1517499, a specific inhibitor that abolishes the tyrosine phosphorylation and nuclear translocation of STAT6 [<xref ref-type="bibr" rid="CR19">19</xref>], also sensitized ALL cells to Ara-C (Fig. <xref rid="Fig1" ref-type="fig">1E</xref>). The cytotoxic activity of various chemotherapeutic drugs were previously ascribed to their capability to induce genotoxicity and apoptosis [<xref ref-type="bibr" rid="CR20">20</xref>]. Indeed, STAT6 knockout or pharmacological inhibition substantially promoted Ara-C-induced apoptosis of ALL cells (Fig. <xref rid="Fig1" ref-type="fig">1F and G</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">1J&#8211;L</xref>), without altering their normal growth (Fig. <xref rid="Fig1" ref-type="fig">1C</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">1M</xref>). To validate the implications of STAT6 knockout in vivo, we used a mouse leukemia xenograft model by injecting parental REH or STAT6-knockout REH cells into NDG mice (Fig. <xref rid="Fig1" ref-type="fig">1H</xref>) and observed no significant impact of STAT6 knockout on leukemogenesis in vivo (Fig. <xref rid="Fig1" ref-type="fig">1I</xref>). In contrast, Ara-C treatment was significantly superior in eradicating STAT6-knockout REH cells rather than their parental REH cells (Fig. <xref rid="Fig1" ref-type="fig">1I</xref>), indicating that STAT6 knockout markedly enhances the sensitivity of ALL cells to Ara-C in vivo. Altogether, these findings reveal that STAT6 deprivation markedly sensitizes ALL cells to Ara-C in vitro and in vivo.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>STAT6 deprivation sensitizes ALL cells to Ara-C.</title><p><bold>A</bold> Gene expression of STAT1 and STAT6 using RNA-Seq analysis of 53 paired diagnosis-relapse ALL specimens. Two sets of data are compared using two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 as a statistically significant difference. <bold>B</bold> Endogenous STAT6 in REH cells was knocked out using CRISPR-Cas9 technology. <bold>C</bold> Growth curve of parental REH and STAT6-knockout REH cells. Data are presented as mean&#8201;&#177;&#8201;SD. <bold>D</bold> Ara-C chemosensitivity of parental REH and STAT6-knockout REH cells as determined by the cell viability assay. Data are presented as a dose-response curve (left panel) and bar graph of IC<sub>50</sub> values (right panel). Each group is compared with the control using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>E</bold> Ara-C chemosensitivity of REH cells (or REH cells pretreated with 10&#8201;nM AS1517499) to Ara-C as determined by the cell viability assay. Data are presented as a dose-response curve (left panel) and bar graph of IC<sub>50</sub> values (right panel), two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>F</bold> The rate of apoptosis in parental REH or STAT6-knockout REH cells treated with increasing concentrations of Ara-C and analyzed by flow cytometry. The quantitative bar graph is shown on the right and data are depicted as mean&#8201;&#177;&#8201;SD, *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01. <bold>G</bold> Ara-C (20&#8201;ng/mL) induces apoptosis in REH cells or REH cells pretreated with 10&#8201;nM AS1517499. The quantitative bar graph and detection of apoptotic biomarker are shown on the right. Data are presented as mean&#8201;&#177;&#8201;SD, each group is compared with the control using two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Schematic diagram showing the construction and drug treatment strategy of mouse xenograft model (<bold>H</bold>) and the number of CD19<sup>+</sup> REH cells isolated from the bone marrow (BM) of mice as analyzed by flow cytometry (<bold>I</bold>). Data are presented as mean&#8201;&#177;&#8201;SD.</p></caption><graphic id="d33e655" position="float" orientation="portrait" xlink:href="41419_2025_7981_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title><italic toggle="yes">TBX21</italic> serves as an indicator of tg-STAT6-enhanced sensitivity of ALL cells to Ara-C</title><p id="Par15">STAT6 belongs to a family of transcription factors that transmits signals from a receptor complex to the nucleus, triggering transcriptional regulation after recruitment of multifarious cofactors to the transcriptosome [<xref ref-type="bibr" rid="CR6">6</xref>]. We therefore performed RNA sequencing of REH cells to explore the mechanism underlying STAT6 knockout in the chemosensitization of ALL cells to Ara-C at the transcriptional level (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>). Given that STAT6 knockout can markedly enhance the chemosensitivity of REH cells to Ara-C and promote Ara-C-induced apoptosis, we first screened out the differentially expressed genes (DEGs) of &#8216;KO25 <italic toggle="yes">vs</italic> CTRL25&#8217;, referred to as &#8216;Cluster &#8544;&#8217;, for STAT6-knockout-mediated enhancement of the proapoptotic effect of Ara-C. We next gathered the DEGs of &#8216;CTRL25 <italic toggle="yes">vs</italic> CTRL&#8217;, referred to as &#8216;Cluster &#8545;&#8217;, for Ara-C acting on REH cells. Theoretically, the intersection between &#8216;Cluster &#8544;&#8217; and &#8216;Cluster &#8545;&#8217; probably masked our target. Based on this rationale, we identified 16 candidate target genes and displayed their relative expression levels via a graphical heatmap (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>). Of these genes, <italic toggle="yes">TBX21</italic> displayed a consistent up-regulation, whereas <italic toggle="yes">FRK</italic> and <italic toggle="yes">GPRIN3</italic> were down-regulated during the comparison of &#8216;Cluster &#8544;&#8217; with &#8216;Cluster &#8545;&#8217; (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). Moreover, complete analysis of the relative expression of these three genes suggested a possible role for <italic toggle="yes">TBX21</italic> in the sensitization of ALL cells to Ara-C via STAT6 knockout (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). However, <italic toggle="yes">TBX21</italic> knockout did not rescue the enhanced sensitization of ALL cells to Ara-C caused by STAT6 knockout (Fig. <xref rid="Fig2" ref-type="fig">2C</xref>). This suggests that <italic toggle="yes">TBX21</italic> was likely an &#8216;indicator&#8217; rather than a &#8216;driver&#8217; throughout the targeting of STAT6 (tg-STAT6) that sensitized ALL cells to Ara-C. We therefore screened a small compound library composed of anticancer monomers of Traditional Chinese Medicine (TCM) and identified a drug monomer called TS1, which downregulated STAT6 expression (Supplementary Fig. <xref rid="MOESM3" ref-type="media">2A</xref>). TS1 specifically reduced <italic toggle="yes">STAT6</italic> gene expression in ALL cells in a time- and dose-dependent manner (Fig. <xref rid="Fig2" ref-type="fig">2D</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">2A&#8211;D</xref>). Given the capacity of TS1 to significantly reduce STAT6 gene expression in ALL cells, TS1 may affect ALL cells through its interplay with Ara-C. To test this hypothesis, we pretreated REH (or 697) cells with TS1 to assess Ara-C-induced apoptosis. The results demonstrated that TS1 synergized with Ara-C to induce ALL cell apoptosis and this synergism was tightly dependent on STAT6 (Fig. <xref rid="Fig2" ref-type="fig">2E and F</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">2E</xref>). Moreover, <italic toggle="yes">TBX21</italic> mRNA levels were directly proportional to the synergistic effect of TS1 with Ara-C (Fig. <xref rid="Fig2" ref-type="fig">2G</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">2F</xref>), which not only echoes the above RNA-Seq data but also establishes the specific role of <italic toggle="yes">TBX21</italic> in tg-STAT6-enhanced chemosensitization of ALL cells to Ara-C.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title><italic toggle="yes">TBX21</italic> serves as an indicator of tg-STAT6-enhanced sensitivity of ALL cells to Ara-C.</title><p><bold>A</bold> Schematic depiction of the RNA sequencing strategy of the indicated REH cells and the intersection of differentially expressed genes (DEGs) between &#8216;Cluster &#8544;&#8217; and &#8216;Cluster &#8545;&#8217; was displayed via a graphical heatmap. Parental REH or STAT6-knockout REH cells were treated with or without 25&#8201;ng/mL Ara-C. <bold>B</bold> The intersection of upregulated DEG (<italic toggle="yes">TBX21</italic>) or downregulated DEGs (<italic toggle="yes">FRK</italic> and <italic toggle="yes">GPRIN3</italic>) between &#8216;Cluster &#8544;&#8217; and &#8216;Cluster &#8545;&#8217;, the histograms of their relative expression are shown on the right. Data are presented as mean&#8201;&#177;&#8201;SD, each group is compared with the control using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>C</bold> Knockout of <italic toggle="yes">TBX21</italic> does not counteract the enhanced chemosensitivity of ALL cells to Ara-C caused by STAT6 knockout. The chemosensitivity of the indicated REH cells to Ara-C is determined by the cell viability assay. <bold>D</bold> Effect of increasing concentrations of TS1 on the mRNA (12&#8201;h) and protein levels (24&#8201;h) of STAT6 in REH cells. Each group is compared with the control using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>E</bold> TS1 (10&#8201;mM, 48&#8201;h) synergizes with Ara-C (20&#8201;ng/mL) to induce apoptosis in REH cells. The quantitative bar graph and the detection of apoptotic biomarker are shown on the left. Data are presented as mean&#8201;&#177;&#8201;SD, each group is compared with the control using two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>F</bold> The synergistic effect of TS1 on Ara-C-induced apoptosis in REH cells is dependent on STAT6. The quantitative bar graph is shown on the left. Data are presented as mean&#8201;&#177;&#8201;SD, two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>G</bold> Relative mRNA levels of <italic toggle="yes">TBX21</italic> in REH cells and REH cells pretreated with TS1 (10&#8201;mM, 48&#8201;h) under the treatment of Ara-C (20&#8201;ng/mL) as determined by real-time quantitative PCR (RT-qPCR). Data are presented as mean&#8201;&#177;&#8201;SD, each group is compared with the control using two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001.</p></caption><graphic id="d33e828" position="float" orientation="portrait" xlink:href="41419_2025_7981_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>STAT6 is SUMOylated on Lys-307</title><p id="Par16">Given the extensive regulation of the STAT family of transcription factors via SUMOylation [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>], we investigated whether STAT6 can also be modified by SUMOylation. We performed a in vivo SUMOylation assay in HEK293 cells with the cotransfection of exogenously-tagged STAT6 and/or SUMO1 with (or without) Myc-UBC9. We observed that UBC9, which is the sole SUMO-specific E2-conjugating enzyme, markedly enhanced STAT6 SUMOylation (Fig. <xref rid="Fig3" ref-type="fig">3A, B</xref>). In contrast, ML792, a SUMO-activating enzyme inhibitor, abolished STAT6 SUMOylation (Fig. <xref rid="Fig3" ref-type="fig">3B</xref>, lane 4 <italic toggle="yes">vs</italic>. lane 2/3). Based on the <italic toggle="yes">SUMOplot</italic><sup><italic toggle="yes">TM</italic></sup>
<italic toggle="yes">Analysis Program</italic>&#8217;s prediction of candidate motifs with high probabilities of SUMO conjugation, we individually mutated the putative SUMO-acceptor Lys to Arg on STAT6 and observed that Lys-307 to Arg-307 (K307R) substitution markedly reduced STAT6 SUMOylation, whereas other mutations failed to do so (Fig. <xref rid="Fig3" ref-type="fig">3C</xref>). Furthermore, the results from a prokaryotic SUMO-conjugation system confirmed STAT6 as a novel SUMOylation target and Lys-307 as a critical SUMO-acceptor site on STAT6 (Fig. <xref rid="Fig3" ref-type="fig">3D</xref>). We also noted that STAT6 can undergo SUMO2-conjugation on Lys-307 (Fig. <xref rid="Fig3" ref-type="fig">3D</xref>), a lysine residue located in the DNA-binding domain (Fig. <xref rid="Fig3" ref-type="fig">3E</xref>), which suggests the potential importance of regulating SUMOylation in STAT6 function.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>STAT6 is SUMOylated on Lys-307.</title><p><bold>A</bold>, <bold>B</bold> STAT6 is SUMOylated in cultured human cells. HEK293 cells were transfected with the indicated plasmids and harvested at 48&#8201;h after transfection, followed by immunoprecipitation (IP) and Western blot (WB) analysis. WCL: whole cell lysate. <bold>C</bold> Lys-307 emerges as a critical SUMO-acceptor site of STAT6. HEK293 cells were transfected with the indicated plasmids and harvested at 48&#8201;h after transfection, followed by IP and WB analysis. <bold>D</bold> STAT6 undergoes SUMOylation on Lys-307 as further confirmed by the prokaryotic SUMO-conjugation system. <bold>E</bold> Schematic diagram of the structural domains of the STAT6 protein.</p></caption><graphic id="d33e893" position="float" orientation="portrait" xlink:href="41419_2025_7981_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>SENP3 targets STAT6 for deSUMOylation in ALL cells</title><p id="Par17">Interestingly, Ara-C specifically induced the expression of the SUMO-specific protease <italic toggle="yes">SENP3</italic> (but not <italic toggle="yes">SENP2</italic>) in REH cells, and this induction of SENP3 was time- and dose-dependent upon Ara-C treatment (Fig. <xref rid="Fig4" ref-type="fig">4A, B</xref>). In addition, Ara-C promoted the association of STAT6 with SENP3 in REH cells (Fig. <xref rid="Fig4" ref-type="fig">4C</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">3A</xref>). We further demonstrated the SUMO2-conjugated SUMOylation of STAT6, and that wild type SENP3 (SENP3<sup>-WT</sup>), but not the catalytic dead SENP3 mutant (SENP3<sup>-C532A</sup>), readily mediated the deSUMOylation of STAT6 (Fig. <xref rid="Fig4" ref-type="fig">4D</xref>). Moreover, SUMO2/3-conjugated SUMOylation of STAT6 significantly accumulated in SENP3 knockdown REH cells (Fig. <xref rid="Fig4" ref-type="fig">4E</xref>). These results indicate that that SENP3 can target STAT6 for deSUMOylation in ALL cells.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>SENP3 targets STAT6 for deSUMOylation in ALL cells.</title><p><bold>A</bold>, <bold>B</bold> Specific induction of SENP3 in REH cells by Ara-C. REH cells were treated with Ara-C for the indicated time and dosage, and then harvested for RT-qPCR or WB analysis. Data are presented as mean&#8201;&#177;&#8201;SD, two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>C</bold> Ara-C induces specific association of STAT6 with SENP3 in REH cells. Whole cell lysates were immunoprecipitated using an anti-STAT6 antibody and then analyzed by WB analysis. <bold>D</bold> SENP3 deSUMOylates SUMO2-conjugated STAT6 in cultured human cells. HEK293 cells were transfected with the indicated plasmids and harvested at 48&#8201;h after transfection, followed by IP and WB analysis. <bold>E</bold> SUMO2/3-conjugated STAT6 accumulates in REH cells upon SENP3 knockdown. Endogenous SENP3 was stably knocked down in REH cells and then analyzed by IP and WB analysis.</p></caption><graphic id="d33e956" position="float" orientation="portrait" xlink:href="41419_2025_7981_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec18"><title>Ara-C-induced SENP3 confers a feedback resistance upon ALL cells</title><p id="Par18">Regarding the chemosensitization of ALL cells to Ara-C via STAT6 targeting, we observed that cells with SENP3 knockdown displayed an enhanced sensitivity to Ara-C but not to 6-TG (Fig. <xref rid="Fig5" ref-type="fig">5A, B</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">3B, C</xref>). Moreover, SENP3 knockdown increased the susceptibility of ALL cells to Ara-C-induced apoptosis and enhanced the sensitivity of ALL cells to Ara-C in vivo (Fig. <xref rid="Fig5" ref-type="fig">5C, D</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">3D</xref>). In particular, the transcriptional status of <italic toggle="yes">TBX21</italic> further revealed the specific role of SENP3 in the chemosensitization of ALL cells to Ara-C via STAT6 targeting (Fig. <xref rid="Fig5" ref-type="fig">5E</xref> and Supplementary Fig. <xref rid="MOESM3" ref-type="media">3E</xref>), hence supporting the notion that Ara-C-induced SENP3 confers a feedback resistance upon ALL cells at least to some extent.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Ara-C-induced SENP3 confers a feedback resistance upon ALL cells.</title><p><bold>A</bold> SENP3 knockdown sensitizes REH cells to Ara-C as determined by the cell viability assay. Data are presented as dose-response curve (left panel) and bar graph of IC<sub>50</sub> values (right panel), two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>B</bold> SENP3 knockdown does not affect the chemosensitivity of cells to 6-TG as determined by the cell viability assay. Data are presented as mean&#8201;&#177;&#8201;SD and the quantitative bar graph is shown at the lower panel. <bold>C</bold> SENP3 knockdown promotes Ara-C-induced apoptosis in REH cells as determined by flow cytometry. Data are presented as mean&#8201;&#177;&#8201;SD and the quantitative bar graph is shown at left panel, two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>D</bold> SENP3 knockdown augments the chemosensitivity of ALL cells to Ara-C in vivo. The number of CD19<sup>+</sup> REH cells from the BM of mice bearing ALL xenografts was determined by flow cytometry. Data are presented as mean&#8201;&#177;&#8201;SD. <bold>E</bold> Relative mRNA levels of <italic toggle="yes">TBX21</italic> in parental REH and SENP3-knockdown REH cells under the treatment of Ara-C (20&#8201;ng/mL) as determined by RT-qPCR. Data are presented as mean&#8201;&#177;&#8201;SD, two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>F</bold> A schematic model for the chemosensitization of ALL cell to Ara-C via STAT6 targeting.</p></caption><graphic id="d33e1041" position="float" orientation="portrait" xlink:href="41419_2025_7981_Fig5_HTML.jpg"/></fig></p></sec></sec><sec id="Sec19" sec-type="discussion"><title>Discussion</title><p id="Par19">All STAT proteins contain six common conserved domains that mediate various aspects of STAT function: N-terminal domain, coiled-coil domain, DNA-binding domain, linker domain, Src homology-2 domain, and transactivation domain (TAD) [<xref ref-type="bibr" rid="CR6">6</xref>]. The specificities of STATs are influenced by divergent TAD, tissue-specific expression and multiple receptor-activated signaling; in addition, dysregulation of STATs often leads to immune system disorders and the development of various malignancies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. STAT6, a key member of the STAT family, can be stimulated primarily by the cytokines IL-4 or IL-13; it acts as a T helper type 2 (Th2)-inducing transcriptional activator in tuning epigenetic modifications and orchestrating the maturation of peripheral Th2 cells [<xref ref-type="bibr" rid="CR25">25</xref>]. In addition, other cytokines, such as IL-3/15, interferon-&#945;, and platelet-derived growth factor (PDGF), activate STAT6 in diverse cell lines and function in nonimmune systems and the pathogenesis of several diseases, including allergic responses, lymphomas, and leukemias [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Based on these findings, targeting STAT6 may be an attractive modality for the treatment of these malignant and non-malignant disorders. In the current study, we unveiled a distinctive role of STAT6 in chemosensitization of ALL cells to Ara-C via various strategies, including gene knockout, pharmacological inhibition, SUMOylation and downregulation of expression. Our findings reveal that STAT6 targeting specifically sensitizes ALL cells to Ara-C. We also explored the molecular mechanism underlying this Ara-C potentiation: tg-STAT6-enhanced chemosensitization of ALL cells to Ara-C was positively correlated with the transcription of <italic toggle="yes">TBX21</italic>, whose coded protein T-bet serves as a bridge between innate and adaptive immunities by regulating a transcriptional network of genetic programs [<xref ref-type="bibr" rid="CR27">27</xref>]. In contrast, deoxycytidine kinase (<italic toggle="yes">dCK</italic>), which catalyzes the intracellular activation of Ara-C [<xref ref-type="bibr" rid="CR28">28</xref>], was not included in these 16 candidate target genes involved in this enhanced Ara-C sensitization. However, our present findings also uncovered that <italic toggle="yes">TBX21</italic> is not the &#8220;driver&#8221; but rather a marker of tg-STAT6-enhanced chemosensitization of ALL cells to Ara-C, although the knockout or downregulation of STAT6 can considerably lead to an increase of Ara-C-induced transcription of <italic toggle="yes">TBX21</italic>. Regarding the relevance of the possible linkage of <italic toggle="yes">TBX21</italic> (or T-bet) to Ara-C chemosensitization, whether STAT6 can exert noncanonical transcriptional inhibition on <italic toggle="yes">TBX21</italic>, warrants further studies.</p><p id="Par20">ALL is the most common childhood cancer, accounting for over 25% of all types of childhood malignancies [<xref ref-type="bibr" rid="CR29">29</xref>]. Chemotherapy remains the most effective approach against ALL, albeit several newly targeted therapies and molecularly targeted agents have been developed for ALL treatment [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, relapse remains a leading cause of mortality, and drug resistance is a major impediment in ALL treatment. Therefore, deciphering the molecular mechanisms underlying resistance to various chemotherapeutic agents as well as designing novel strategies to surmount chemoresistance are of paramount importance for curative treatment of ALL. As a step towards this end, we herein first found that relapsed ALL specimens exhibit a substantially lower STAT6 expression compared with their paired diagnosis specimens; this differs from previous studies, which showed a high expression of STAT6 in various tumors and its association with tumorigenesis and poor prognosis in human cancers [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR32">32</xref>]. Thus, notably, targeting STAT6 can specifically enhance the chemosensitization of ALL cells to Ara-C by boosting Ara-C-induced apoptosis; this implies that STAT6 targeting may prove as a novel modality to surmount Ara-C resistance in ALL. In this regard, we verified that TS1, a lipid-soluble phenanthraquinone extracted from the root of TCM <italic toggle="yes">Salvia miltiorrhiza</italic> and displaying favorable activities in antioxidant, anti-inflammatory, anti-cancer as well as plays a role in the regulation of cell autophagy or apoptosis [<xref ref-type="bibr" rid="CR33">33</xref>], can synergize with Ara-C to induce apoptosis in ALL cells by reducing STAT6 expression. This phenomenon was in direct correlation to the transcription of <italic toggle="yes">TBX21</italic>. In summary, these findings provide not only a potential therapeutic target for overcoming Ara-C resistance but also a novel strategy for the combined application of TCM and Western medicine in the treatment of ALL.</p><p id="Par21">We have also discovered that STAT6 undergoes SUMOylation, which is an essential posttranslational modification considered a similar enzymatic machinery to ubiquitination [<xref ref-type="bibr" rid="CR34">34</xref>]. In particular, switching on or off SUMOylation involves a dimeric E1 (SAE1/UBA2), a single E2 (UBC9), a limited quantity of E3, and mainly, a deSUMOylase family [<xref ref-type="bibr" rid="CR35">35</xref>]. The latter comprises six SENPs (SENP1&#8211;3 and 5&#8211;7), which play decisive roles in SUMO maturation/cycling and protein SUMOylation [<xref ref-type="bibr" rid="CR36">36</xref>]. However, studies rarely depicted the association between SENPs and ALL. We previously reported that SENP1, rather than SENP2, can specifically mediate the antileukemic effects of topoisomerase &#8544; inhibitors like camptothecin derivatives and topotecan on ALL. In contrast, neither SENP1 nor SENP2 altered the chemosensitivity of ALL cells to diverse chemotherapeutic drugs [<xref ref-type="bibr" rid="CR37">37</xref>]. Here, we found that SENP3, which shows a preference for SUMO2/3-conjugated deSUMOylation unlike SENP1/2 [<xref ref-type="bibr" rid="CR36">36</xref>], targets STAT6 for deSUMOylation in ALL cells. To the best of our knowledge, no previous study reported the relevance of SENP3 in ALL, although SENP3 plays important roles in acute myeloblastic leukemia (AML), promyelocytic leukemia (PML) and osteogenic differentiation of stem cells [<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>]. Most importantly, Ara-C specifically induces SENP3 expression in ALL cells, and SENP3 knockdown considerably sensitizes ALL cells to Ara-C, with a similar impact of targeting STAT6. This suggests that Ara-C-induced SENP3 expression confers upon ALL cells a feedback resistance. Overall, our findings reveal a novel role of STAT6 in ALL cells and validate multiple effective strategies for targeting STAT6 (Fig. <xref rid="Fig5" ref-type="fig">5F</xref>) and thus provide potential new avenues for overcoming of Ara-C resistance in future ALL treatment.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="41419_2025_7981_MOESM1_ESM.pptx" position="float" orientation="portrait"><caption><p>Supplementary Figure 1-3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="41419_2025_7981_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Figure Legends</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xlink:href="41419_2025_7981_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Original Data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p>Edited by Marc Diederich</p></fn><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Shuzhang Sun, Yixuan Cheng, Xiange Huang, Yinjie Yan.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41419-025-07981-7.</p></sec><ack><title>Acknowledgements</title><p>The authors sincerely thank Prof. Bin-Bing S Zhou (Shanghai Children&#8217;s Medical Center), Prof. Pei-Yong Zheng and Lei Zhou (Longhua Hospital) for their kind help. This study was supported by the grants from National Natural Science Foundation of China (82070159 to H. Li. and 81872252 to N. Xiao), National Health Commission (2024ZD0521101 to H-G. Li), and National Administration of Traditional Chinese Medicine (zyyzdxk-2023063 to H-G. Li); the funds from Science and Technology Commission of Shanghai Municipality (21MC1930500 to H-G. Li), Shanghai Municipal Health Commission (shslczdzk03701 to H-G. Li), Shanghai University of Traditional Chinese Medicine Longhua Hospital (KY22012 to Y-J. Yan), and Pudong Health Commission (PW2024D-13, PDZY-2020-0406).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>H-G Li, H Li, and N Xiao designed the research and analyzed the data; S-Z Sun, Y-X Cheng, X-G Huang, Y-J Yan, W-X Hou, H-S Fang, and Y Chen conducted the experiments; C-S Ma, Y-M Lu, Z-Y Zhou and YGA provided guidance and directed the research; S-Z Sun, YGA, H Li and N Xiao wrote the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data and materials will be made available on request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par22">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics statement</title><p id="Par23">The patient samples obtained in this study comply with both the Declarations of Helsinki and Istanbul. They were evaluated and approved by the Institutional Review Board of Shanghai Children&#8217;s Medical Center (SCMC, Permit No. SCMCIRB-K2022098-1). All the patients have signed informed consent. Animal studies in this study followed the ARRIVE guidelines. They were evaluated and approved by the Institutional Animal Care and Use Committee of SCMC (Permit No. SCMC-LAWEC-2023-118).</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Jacoby E, Gokbuget N, Nagler A. Adult Acute Lymphoblastic Leukaemia. In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook. Cham (CH) 2022. p. 61&#8211;6.<pub-id pub-id-type="pmid">36122035</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Bader P, Locatelli F, Peters C. Paediatric Acute Lymphoblastic Leukaemia (ALL). In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook. Cham (CH) 2022. p. 57&#8211;9.<pub-id pub-id-type="pmid">36122054</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malard</surname><given-names>F</given-names></name><name name-style="western"><surname>Mohty</surname><given-names>M</given-names></name></person-group><article-title>Acute lymphoblastic leukaemia</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1146</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">32247396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)33018-1</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146&#8211;62.<pub-id pub-id-type="pmid">32247396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)33018-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inaba</surname><given-names>H</given-names></name><name name-style="western"><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><article-title>Pediatric acute lymphoblastic leukemia</article-title><source>Haematologica</source><year>2020</year><volume>105</volume><fpage>2524</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">33054110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2020.247031</pub-id><pub-id pub-id-type="pmcid">PMC7604619</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524&#8211;39.<pub-id pub-id-type="pmid">33054110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2020.247031</pub-id><pub-id pub-id-type="pmcid">PMC7604619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunger</surname><given-names>SP</given-names></name><name name-style="western"><surname>Raetz</surname><given-names>EA</given-names></name></person-group><article-title>How I treat relapsed acute lymphoblastic leukemia in the pediatric population</article-title><source>Blood</source><year>2020</year><volume>136</volume><fpage>1803</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">32589723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019004043</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136:1803&#8211;12.<pub-id pub-id-type="pmid">32589723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019004043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J</given-names></name><name name-style="western"><surname>Babon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G</given-names></name><name name-style="western"><surname>Lang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Correction: The JAK-STAT pathway: from structural biology to cytokine engineering</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><fpage>290</fpage><pub-id pub-id-type="pmid">39419998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01975-1</pub-id><pub-id pub-id-type="pmcid">PMC11487187</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, et al. Correction: The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. 2024;9:290.<pub-id pub-id-type="pmid">39419998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01975-1</pub-id><pub-id pub-id-type="pmcid">PMC11487187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goenka</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>MH</given-names></name></person-group><article-title>Transcriptional regulation by STAT6</article-title><source>Immunol Res</source><year>2011</year><volume>50</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">21442426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-011-8205-2</pub-id><pub-id pub-id-type="pmcid">PMC3107597</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res. 2011;50:87&#8211;96.<pub-id pub-id-type="pmid">21442426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-011-8205-2</pub-id><pub-id pub-id-type="pmcid">PMC3107597</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>N</given-names></name><name name-style="western"><surname>Liongue</surname><given-names>C</given-names></name><name name-style="western"><surname>Ward</surname><given-names>AC</given-names></name></person-group><article-title>STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer</article-title><source>J Hematol Oncol</source><year>2021</year><volume>14</volume><fpage>198</fpage><pub-id pub-id-type="pmid">34809691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-021-01214-y</pub-id><pub-id pub-id-type="pmcid">PMC8607625</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Awasthi N, Liongue C, Ward AC. STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J Hematol Oncol. 2021;14:198.<pub-id pub-id-type="pmid">34809691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-021-01214-y</pub-id><pub-id pub-id-type="pmcid">PMC8607625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sehgal</surname><given-names>PB</given-names></name></person-group><article-title>Non-genomic STAT5-dependent effects at the endoplasmic reticulum and Golgi apparatus and STAT6-GFP in mitochondria</article-title><source>JAKSTAT</source><year>2013</year><volume>2</volume><fpage>e24860</fpage><pub-id pub-id-type="pmid">24470974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/jkst.24860</pub-id><pub-id pub-id-type="pmcid">PMC3894245</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sehgal PB. Non-genomic STAT5-dependent effects at the endoplasmic reticulum and Golgi apparatus and STAT6-GFP in mitochondria. JAKSTAT. 2013;2:e24860.<pub-id pub-id-type="pmid">24470974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/jkst.24860</pub-id><pub-id pub-id-type="pmcid">PMC3894245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheon</surname><given-names>H</given-names></name><name name-style="western"><surname>Stark</surname><given-names>GR</given-names></name></person-group><article-title>Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>9373</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19478064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0903487106</pub-id><pub-id pub-id-type="pmcid">PMC2688000</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA. 2009;106:9373&#8211;8.<pub-id pub-id-type="pmid">19478064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0903487106</pub-id><pub-id pub-id-type="pmcid">PMC2688000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Affolter</surname><given-names>M</given-names></name><name name-style="western"><surname>Pyrowolakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Basler</surname><given-names>K</given-names></name></person-group><article-title>Signal-induced repression: the exception or the rule in developmental signaling?</article-title><source>Dev Cell</source><year>2008</year><volume>15</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18606137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2008.06.006</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Affolter M, Pyrowolakis G, Weiss A, Basler K. Signal-induced repression: the exception or the rule in developmental signaling?. Dev Cell. 2008;15:11&#8211;22.<pub-id pub-id-type="pmid">18606137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2008.06.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ren</surname><given-names>XR</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification of tanshinone I as a natural Cu(II) ionophore</article-title><source>Free Radic Biol Med</source><year>2025</year><volume>227</volume><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">39613045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2024.11.049</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Zheng YL, Ji Y, Li Y, Yan S, Ren XR, Tang W, et al. Identification of tanshinone I as a natural Cu(II) ionophore. Free Radic Biol Med. 2025;227:27&#8211;41.<pub-id pub-id-type="pmid">39613045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2024.11.049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>SUMOylation is required for PIPK1gamma-driven keratinocyte migration and growth</article-title><source>FEBS J</source><year>2019</year><volume>286</volume><fpage>4709</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">31276292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.14978</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ni W, Li Y, Cai L, Dong C, Fang H, Chen Y, et al. SUMOylation is required for PIPK1gamma-driven keratinocyte migration and growth. FEBS J. 2019;286:4709&#8211;20.<pub-id pub-id-type="pmid">31276292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.14978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>T</given-names></name><etal/></person-group><article-title>SENP2-NDR2-p21 axis modulates lung cancer cell growth</article-title><source>Eur J Pharm</source><year>2024</year><volume>978</volume><fpage>176761</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2024.176761</pub-id><pub-id pub-id-type="pmid">38908669</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cheng Y, Hou W, Fang H, Yan Y, Lu Y, Meng T, et al. SENP2-NDR2-p21 axis modulates lung cancer cell growth. Eur J Pharm. 2024;978:176761.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2024.176761</pub-id><pub-id pub-id-type="pmid">38908669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Gu</surname><given-names>C</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>SUMO-specific protease 2 (SENP2) suppresses keratinocyte migration by targeting NDR1 for de-SUMOylation</article-title><source>FASEB J</source><year>2019</year><volume>33</volume><fpage>163</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29969578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201800353R</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Xiao N, Li H, Yu W, Gu C, Fang H, Peng Y, et al. SUMO-specific protease 2 (SENP2) suppresses keratinocyte migration by targeting NDR1 for de-SUMOylation. FASEB J. 2019;33:163&#8211;74.<pub-id pub-id-type="pmid">29969578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201800353R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Mei</surname><given-names>W</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name></person-group><article-title>SUMOylation attenuates human beta-arrestin 2 inhibition of IL-1R/TRAF6 signaling</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><fpage>1927</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">25425640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.608703</pub-id><pub-id pub-id-type="pmcid">PMC4303650</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Xiao N, Li H, Mei W, Cheng J. SUMOylation attenuates human beta-arrestin 2 inhibition of IL-1R/TRAF6 signaling. J Biol Chem. 2015;290:1927&#8211;35.<pub-id pub-id-type="pmid">25425640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.608703</pub-id><pub-id pub-id-type="pmcid">PMC4303650</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchimura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugasawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>M</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>H</given-names></name></person-group><article-title>Overproduction of eukaryotic SUMO-1- and SUMO-2-conjugated proteins in Escherichia coli</article-title><source>Anal Biochem</source><year>2004</year><volume>331</volume><fpage>204</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15246018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ab.2004.04.034</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Uchimura Y, Nakamura M, Sugasawa K, Nakao M, Saitoh H. Overproduction of eukaryotic SUMO-1- and SUMO-2-conjugated proteins in Escherichia coli. Anal Biochem. 2004;331:204&#8211;6.<pub-id pub-id-type="pmid">15246018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ab.2004.04.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Brady</surname><given-names>SW</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia</article-title><source>Blood</source><year>2020</year><volume>135</volume><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">31697823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019002220</pub-id><pub-id pub-id-type="pmcid">PMC6940198</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41&#8211;55.<pub-id pub-id-type="pmid">31697823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019002220</pub-id><pub-id pub-id-type="pmcid">PMC6940198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binnemars-Postma</surname><given-names>K</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>R</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>J</given-names></name></person-group><article-title>Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer</article-title><source>FASEB J</source><year>2018</year><volume>32</volume><fpage>969</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">29066614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201700629R</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Binnemars-Postma K, Bansal R, Storm G, Prakash J. Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB J. 2018;32:969&#8211;78.<pub-id pub-id-type="pmid">29066614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201700629R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesner</surname><given-names>PW</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Budihardjo</surname><given-names>II</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>SH</given-names></name></person-group><article-title>Chemotherapy-induced apoptosis</article-title><source>Adv Pharm</source><year>1997</year><volume>41</volume><fpage>461</fpage><lpage>99</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1054-3589(08)61069-8</pub-id><pub-id pub-id-type="pmid">9204156</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Mesner PW Jr., Budihardjo II, Kaufmann SH. Chemotherapy-induced apoptosis. Adv Pharm. 1997;41:461&#8211;99.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1054-3589(08)61069-8</pub-id><pub-id pub-id-type="pmid">9204156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Begitt</surname><given-names>A</given-names></name><name name-style="western"><surname>Droescher</surname><given-names>M</given-names></name><name name-style="western"><surname>Knobeloch</surname><given-names>KP</given-names></name><name name-style="western"><surname>Vinkemeier</surname><given-names>U</given-names></name></person-group><article-title>SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNgamma</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>1002</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21636857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-04-347930</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNgamma. Blood. 2011;118:1002&#8211;7.<pub-id pub-id-type="pmid">21636857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-04-347930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Nguyen</surname><given-names>T</given-names></name><name name-style="western"><surname>Angkasekwinai</surname><given-names>P</given-names></name><name name-style="western"><surname>Dou</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>FM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>LS</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation</article-title><source>Mol Cell</source><year>2012</year><volume>45</volume><fpage>210</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">22284677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2011.12.026</pub-id><pub-id pub-id-type="pmcid">PMC3269036</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Van Nguyen T, Angkasekwinai P, Dou H, Lin FM, Lu LS, Cheng J, et al. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell. 2012;45:210&#8211;21.<pub-id pub-id-type="pmid">22284677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2011.12.026</pub-id><pub-id pub-id-type="pmcid">PMC3269036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Chin</surname><given-names>YE</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>5826</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">27181202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2016.124</pub-id><pub-id pub-id-type="pmcid">PMC5116054</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zhou Z, Wang M, Li J, Xiao M, Chin YE, Cheng J, et al. SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer. Oncogene. 2016;35:5826&#8211;38.<pub-id pub-id-type="pmid">27181202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2016.124</pub-id><pub-id pub-id-type="pmcid">PMC5116054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Xiao J, Sun F, Wang YN, Liu B, Zhou P, Wang FX, et al. UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer. J Clin Invest. 2023;133:e158352.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI158352</pub-id><pub-id pub-id-type="pmcid">PMC9927932</pub-id><pub-id pub-id-type="pmid">36626227</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name></person-group><article-title>STATs, promising targets for the treatment of autoimmune and inflammatory diseases</article-title><source>Eur J Med Chem</source><year>2024</year><volume>277</volume><fpage>116783</fpage><pub-id pub-id-type="pmid">39180944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.116783</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">He X, Liu P, Luo Y, Fu X, Yang T. STATs, promising targets for the treatment of autoimmune and inflammatory diseases. Eur J Med Chem. 2024;277:116783.<pub-id pub-id-type="pmid">39180944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.116783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>The roles of post-translational modifications and coactivators of STAT6 signaling in tumor growth and progression</article-title><source>Future Med Chem</source><year>2020</year><volume>12</volume><fpage>1945</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">32779479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc-2020-0224</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Huang H, Zheng Y, Li L, Shi W, Zhang R, Liu H, et al. The roles of post-translational modifications and coactivators of STAT6 signaling in tumor growth and progression. Future Med Chem. 2020;12:1945&#8211;60.<pub-id pub-id-type="pmid">32779479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc-2020-0224</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarevic</surname><given-names>V</given-names></name><name name-style="western"><surname>Glimcher</surname><given-names>LH</given-names></name><name name-style="western"><surname>Lord</surname><given-names>GM</given-names></name></person-group><article-title>T-bet: a bridge between innate and adaptive immunity</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><fpage>777</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">24113868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3536</pub-id><pub-id pub-id-type="pmcid">PMC6290922</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13:777&#8211;89.<pub-id pub-id-type="pmid">24113868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3536</pub-id><pub-id pub-id-type="pmcid">PMC6290922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szelest</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannopoulos</surname><given-names>K</given-names></name></person-group><article-title>Targeting splicing for hematological malignancies therapy</article-title><source>BMC Genomics</source><year>2024</year><volume>25</volume><fpage>1067</fpage><pub-id pub-id-type="pmid">39528914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12864-024-10975-y</pub-id><pub-id pub-id-type="pmcid">PMC11552377</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Szelest M, Giannopoulos K. Targeting splicing for hematological malignancies therapy. BMC Genomics. 2024;25:1067.<pub-id pub-id-type="pmid">39528914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12864-024-10975-y</pub-id><pub-id pub-id-type="pmcid">PMC11552377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>DA</given-names></name><name name-style="western"><surname>King</surname><given-names>J</given-names></name><name name-style="western"><surname>Tai</surname><given-names>E</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>N</given-names></name><name name-style="western"><surname>Ajani</surname><given-names>UA</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009</article-title><source>Pediatrics</source><year>2014</year><volume>134</volume><fpage>e945</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">25201796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2013-3926</pub-id><pub-id pub-id-type="pmcid">PMC4536809</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J. Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics. 2014;134:e945&#8211;55.<pub-id pub-id-type="pmid">25201796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2013-3926</pub-id><pub-id pub-id-type="pmcid">PMC4536809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Roth</surname><given-names>CP</given-names></name><name name-style="western"><surname>Wasson</surname><given-names>LM</given-names></name><name name-style="western"><surname>Vishwanatha</surname><given-names>JK</given-names></name></person-group><article-title>Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer</article-title><source>Prostate</source><year>2007</year><volume>67</volume><fpage>1550</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">17705178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pros.20640</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate. 2007;67:1550&#8211;64.<pub-id pub-id-type="pmid">17705178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pros.20640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CG</given-names></name><name name-style="western"><surname>Ye</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>FF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>2421</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20480530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v16.i19.2421</pub-id><pub-id pub-id-type="pmcid">PMC2874149</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol. 2010;16:2421&#8211;7.<pub-id pub-id-type="pmid">20480530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v16.i19.2421</pub-id><pub-id pub-id-type="pmcid">PMC2874149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abroun</surname><given-names>S</given-names></name><name name-style="western"><surname>Saki</surname><given-names>N</given-names></name><name name-style="western"><surname>Ahmadvand</surname><given-names>M</given-names></name><name name-style="western"><surname>Asghari</surname><given-names>F</given-names></name><name name-style="western"><surname>Salari</surname><given-names>F</given-names></name><name name-style="western"><surname>Rahim</surname><given-names>F</given-names></name></person-group><article-title>STATs: An Old Story, Yet Mesmerizing</article-title><source>Cell J</source><year>2015</year><volume>17</volume><fpage>395</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">26464811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22074/cellj.2015.1</pub-id><pub-id pub-id-type="pmcid">PMC4601860</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F. STATs: An Old Story, Yet Mesmerizing. Cell J. 2015;17:395&#8211;411.<pub-id pub-id-type="pmid">26464811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22074/cellj.2015.1</pub-id><pub-id pub-id-type="pmcid">PMC4601860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tanshinone I: Pharmacological activities, molecular mechanisms against diseases and future perspectives</article-title><source>Phytomedicine</source><year>2022</year><volume>110</volume><fpage>154632</fpage><pub-id pub-id-type="pmid">36608501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2022.154632</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ke L, Zhong C, Chen Z, Zheng Z, Li S, Chen B, et al. Tanshinone I: Pharmacological activities, molecular mechanisms against diseases and future perspectives. Phytomedicine. 2022;110:154632.<pub-id pub-id-type="pmid">36608501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2022.154632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geiss-Friedlander</surname><given-names>R</given-names></name><name name-style="western"><surname>Melchior</surname><given-names>F</given-names></name></person-group><article-title>Concepts in sumoylation: a decade on</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>947</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">18000527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm2293</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8:947&#8211;56.<pub-id pub-id-type="pmid">18000527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm2293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Kunz K, Piller T, Muller S. SUMO-specific proteases and isopeptidases of the SENP family at a glance. J Cell Sci. 2018;131:jcs211904.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.211904</pub-id><pub-id pub-id-type="pmid">29559551</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vertegaal</surname><given-names>ACO</given-names></name></person-group><article-title>Signalling mechanisms and cellular functions of SUMO</article-title><source>Nat Rev Mol Cell Biol</source><year>2022</year><volume>23</volume><fpage>715</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">35750927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-022-00500-y</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022;23:715&#8211;31.<pub-id pub-id-type="pmid">35750927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-022-00500-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2022</year><volume>1868</volume><fpage>166492</fpage><pub-id pub-id-type="pmid">35850175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2022.166492</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Niu Q, Hou W, Yan Y, Sun S, Lin Y, Fang H, et al. Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166492.<pub-id pub-id-type="pmid">35850175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2022.166492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>ET</given-names></name><etal/></person-group><article-title>SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>12906</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">20181954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M109.071431</pub-id><pub-id pub-id-type="pmcid">PMC2857110</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Han Y, Huang C, Sun X, Xiang B, Wang M, Yeh ET, et al. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem. 2010;285:12906&#8211;15.<pub-id pub-id-type="pmid">20181954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M109.071431</pub-id><pub-id pub-id-type="pmcid">PMC2857110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>3812</fpage><pub-id pub-id-type="pmid">31444354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-11795-5</pub-id><pub-id pub-id-type="pmcid">PMC6707248</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Xu R, Yu S, Zhu D, Huang X, Xu Y, Lao Y, et al. hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy. Nat Commun. 2019;10:3812.<pub-id pub-id-type="pmid">31444354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-11795-5</pub-id><pub-id pub-id-type="pmcid">PMC6707248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayak</surname><given-names>A</given-names></name><name name-style="western"><surname>Viale-Bouroncle</surname><given-names>S</given-names></name><name name-style="western"><surname>Morsczeck</surname><given-names>C</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name></person-group><article-title>The SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 methyltransferase complexes and controls osteogenic differentiation</article-title><source>Mol Cell</source><year>2014</year><volume>55</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">24930734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2014.05.011</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Nayak A, Viale-Bouroncle S, Morsczeck C, Muller S. The SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 methyltransferase complexes and controls osteogenic differentiation. Mol Cell. 2014;55:47&#8211;58.<pub-id pub-id-type="pmid">24930734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2014.05.011</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>